Veloxis Pharmaceuticals to Present at 14th Annual BIO CEO & Investor Conference MarketWatch (press release) Dr. Polvino will present an overview of the company and discuss top-line Phase 3 results of LCP-Tacro(TM), Veloxis' candidate to prevent organ transplant rejection. Based in Horsholm, Denmark, with an office in New Jersey, Veloxis Pharmaceuticals A/S, ... |
